<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007977</url>
  </required_header>
  <id_info>
    <org_study_id>ZT01-CL-1003</org_study_id>
    <nct_id>NCT05007977</nct_id>
  </id_info>
  <brief_title>Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus</brief_title>
  <official_title>Pharmacodynamic Evaluation of ZT-01 in a Stepped Hypoglycemic Clamp Model in Subjects With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zucara Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zucara Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ZT-01 increases the glucagon response to&#xD;
      hypoglycemia in type 1 diabetes (T1D). ZT-01 is a specific somatostatin (SST) type 2 receptor&#xD;
      antagonist hypothesized to increase the counterregulatory glucagon release during&#xD;
      hypoglycemia, which is impaired in diabetes, and may thus reduce the occurrence of&#xD;
      hypoglycemia.&#xD;
&#xD;
      Approximately 25 participants with well-controlled type 1 diabetes will be recruited to a&#xD;
      crossover study and be randomized to the order in which they receive a single administration&#xD;
      of placebo, low dose and high dose ZT-01 during three euglycemic-hypoglycemic clamps 2 to 6&#xD;
      weeks apart, with a follow-up visit approximately 1 week after the final clamp.&#xD;
&#xD;
      Participants will stay overnight in the clinic before each clamp, and their plasma glucose&#xD;
      (PG) will be kept at euglycemic levels with IV insulin and dextrose as needed. The following&#xD;
      morning, the clamp will begin and the subject's PG will be kept at 5.5 mmol/L (euglycemia)&#xD;
      with variable IV insulin (and dextrose as needed). Study treatment will be administered&#xD;
      during this euglycemic period, and then insulin will be increased so that PG falls to a&#xD;
      plateau of mild hypoglycemia, and then increased further to clinically significant&#xD;
      hypoglycemia. Release of glucagon and other counterregulatory hormones will be measured, and&#xD;
      a symptom score will be completed, during euglycemia before and following study treatment,&#xD;
      and during each level of hypoglycemia. Following the clamp, the participant's blood glucose&#xD;
      will be returned to normal levels prior to leaving the clinic.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to the order in which they receive three treatments during consecutive clamps</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The participant, the investigator and site staff conducting all study procedures are masked to treatment administered at each clamp.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glucagon between euglycemia and hypoglycemia</measure>
    <time_frame>During each clamp, up to 12 weeks</time_frame>
    <description>Mean and peak glucagon level during euglycemia and each hypoglycemic period of the clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin infused</measure>
    <time_frame>During each clamp, up to 12 weeks</time_frame>
    <description>Insulin administered during euglycemia and each hypoglycemic period of the clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin infusion rate</measure>
    <time_frame>During each clamp, up to 12 weeks</time_frame>
    <description>Rate of insulin administered during euglycemia and each hypoglycemic period of the clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in catecholamines between euglycemia and hypoglycemia</measure>
    <time_frame>During each clamp, up to 12 weeks</time_frame>
    <description>Epinephrine and norepinephrine during euglycemia and each stable hypoglycemic period of the clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in growth hormone between euglycemia and hypoglycemia</measure>
    <time_frame>During each clamp, up to 12 weeks</time_frame>
    <description>Growth hormone during euglycemia and each stable hypoglycemic period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cortisol between euglycemia and hypoglycemia</measure>
    <time_frame>During each clamp, up to 12 weeks</time_frame>
    <description>Cortisol during euglycemia and each stable hypoglycemic period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Symptom score during hypoglycemia</measure>
    <time_frame>During each clamp, up to 12 weeks</time_frame>
    <description>The Edinburgh hypoglycemia symptom score assesses the presence and extent (on a scale of 1, not present to 7, present a great deal) of 16 common symptoms which may be experienced by an individual while their blood glucose is low. The score does not indicate any outcome.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Treatment order: placebo, low dose, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single administration of each treatment in this order during three consecutive clamps</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment order: placebo, high dose, low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single administration of each treatment in this order during three consecutive clamps</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment order: low dose, placebo, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single administration of each treatment in this order during three consecutive clamps</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment order: low dose, high dose, placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single administration of each treatment in this order during three consecutive clamps</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment order: high dose, placebo, low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single administration of each treatment in this order during three consecutive clamps</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment order: high dose, low dose, placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single administration of each treatment in this order during three consecutive clamps</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZT-01 low dose</intervention_name>
    <description>Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp</description>
    <arm_group_label>Treatment order: high dose, low dose, placebo</arm_group_label>
    <arm_group_label>Treatment order: high dose, placebo, low dose</arm_group_label>
    <arm_group_label>Treatment order: low dose, high dose, placebo</arm_group_label>
    <arm_group_label>Treatment order: low dose, placebo, high dose</arm_group_label>
    <arm_group_label>Treatment order: placebo, high dose, low dose</arm_group_label>
    <arm_group_label>Treatment order: placebo, low dose, high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZT-01 high dose</intervention_name>
    <description>Single SC injection of ZT-01 20 mg during hypoglycemic clamp</description>
    <arm_group_label>Treatment order: high dose, low dose, placebo</arm_group_label>
    <arm_group_label>Treatment order: high dose, placebo, low dose</arm_group_label>
    <arm_group_label>Treatment order: low dose, high dose, placebo</arm_group_label>
    <arm_group_label>Treatment order: low dose, placebo, high dose</arm_group_label>
    <arm_group_label>Treatment order: placebo, high dose, low dose</arm_group_label>
    <arm_group_label>Treatment order: placebo, low dose, high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single SC injection of placebo during hypoglycemic clamp</description>
    <arm_group_label>Treatment order: high dose, low dose, placebo</arm_group_label>
    <arm_group_label>Treatment order: high dose, placebo, low dose</arm_group_label>
    <arm_group_label>Treatment order: low dose, high dose, placebo</arm_group_label>
    <arm_group_label>Treatment order: low dose, placebo, high dose</arm_group_label>
    <arm_group_label>Treatment order: placebo, high dose, low dose</arm_group_label>
    <arm_group_label>Treatment order: placebo, low dose, high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes for at least 5 years and receiving insulin as the only T1D therapy&#xD;
&#xD;
          -  HbA1c ≥6.0 and ≤9.0 %&#xD;
&#xD;
          -  BMI ≥18 to ≤27 kg/m^2&#xD;
&#xD;
          -  Normal thyroid function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impaired hypoglycemia awareness&#xD;
&#xD;
          -  Severe hypoglycemia or diabetic ketoacidosis (DKA) within 3 months&#xD;
&#xD;
          -  Abnormal blood pressure or ECG, clinically significant cardiovascular, cerebrovascular&#xD;
             or peripheral vascular disease&#xD;
&#xD;
          -  History of pheochromocytoma, insulinoma, glucagonoma, acromegaly, Cushing's disease,&#xD;
             glycogen storage disease or adrenal insufficiency; ongoing or previous treatment with&#xD;
             octreotide, lanreotide or pasireotide&#xD;
&#xD;
          -  Current use of systemic corticosteroids or beta-blockers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Liggins, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Zucara Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LMC Manna Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manager, Patient Recruitment &amp; Retention</last_name>
      <phone>1-833-323-JOIN</phone>
      <email>research@LMCmanna.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Abitbol, MDCM, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypoglycemic clamp</keyword>
  <keyword>glucagon counterregulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

